 Dr Bernhard Ryffel,
MD, Professor, Director UMR6218, Molecular Immunology, University and CNRS, France Education: Medicine, University of Bern, Switzerland 1967-1973, habilitation Uni Basel (PhD), Board examination in pathology, FMR and SARPC.
Positions held: Professor and Head of Pharma-Toxicology of the Institute of Toxicology Zurich, Professor and Head of Department of Immunology, University of Cape Town, RSA; Since 2001 Director CNRS, immunology Orleans, France
Main areas of research
Inflammatory diseases, identification of pathways and targets in ARDS, asthma, allergy, CPOD and lung fibrosis.
Advisory board
Expert of AFSSAPS and AFFSET, France, Wellcome Trust, UK (regular reviewer), and European Community, Brussels
Board of journals
Medical Microbiology and Immunology, Microbes and Infection, International Journal of Experimental Pathology, Drug Discovery Today: Disease Models, Regulatory Toxicology and Pharmacology
Advisor of companies
PhenoTec AG, IBR AG, Xigen SA, MedImmune SA, Actelion and Novartis in Switzerland; KeyObs and GreenPharma, France; Novocure, Isreal, Xencor, Amgen and Genentech USA,
Referee for Journals
Regular reviewer for J Immunology, J Clinical Investigation, J Exp Medicine, J Immunol,
Infection and Immunity, J Infectious Disease, Mol Cell Biol, J Biol Chem,
Parasitology, Laboratory Investigations, Am J Pathology, PNAS and others
Appearing: Conference Day One: Wednesday, 17 March 2010 12.05 Validation of Novel Drug Targets – Lung Inflammation Dr Bernhard Ryffel, MD, Professor, Director,
UMR6218, Molecular Immunology, University and CNRS, France |
|
|
|
|
|
Session sponsor:
Exhibitors:
|
asia research institution poster presentation
* For first 20 confirmed poster presentations
|
|
|
